Decision Resources, one of the industry's leading research and advisory firms for pharmaceutical and healthcare issues, published a report with the findings staing that the emergence of cancer vaccines, including drugs from Pharmexa and Cell Genesys, will be the key factor driving the pancreatic cancer drug market to more than double by 2016.
A report from Pharmacor finds that Pharmexa's GV1001 and Cell Genesys's GVAX will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
The report also finds that as a result of the generic drugs markt sales of cytotoxic therapies used in pancreatic cancer -- Eli Lilly's Gemzar, Sanofi-Aventis's Eloxatin/Yakult Honsha's Elplat, Pfizer/Yakult's Campto/Camptosar, Daiichi-Sankyo's Topotecin, and Sanofi-Aventis's Taxotere -- will decline significantly during the next decade.
Although it accounts for only about two percent of all cancers, pancreatic cancer -- one of the most difficult cancers to treat -- is the fourth leading cause of cancer deaths in the United States.
New methods to treat the disease can create a huge opportunity for spirited development and competition in the market. Resulting in even more effective therapies that can improve survival and generate more business.
